The authors concluded that exenatide significantly improved coronary endothelial function in patients with newly diagnosed T2DM, and that this effect was likely mediated primarily through activation of AMPK and the PI3K/Akt pathway in a GLP-1R/cAMP-dependent manner [246]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.